Growth and development of very low birthweight infants recovering from bronchopulmonary dysplasia.

Yu, V. Y. H.; Orgill, A. A.; Lim, Sok Bee; Bajuk, Barbara; Astbury, Jill

doi:10.1136/adc.58.10.791

Cited by 101 publications

(25 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Paradoxically, the initial course of BPD survivors during the neonatal period may even appear favorable, being characterized by a gradually declining need for supplementary oxygen [4,6,7]. In this study the majority (75%) of BPD cases were weaned off oxygen before term, and none were sent home on oxygen [11].…”

Section: Discussionmentioning

confidence: 68%

“…Gestational immaturity is the main prerequisite for the development of BPD [3]. Similarly to previous reports [4,6], we decided not only to relate the occurrence of BPD to a complete preterm birth cohort but also to explore more precise defintions for the population at risk. In a previous study [6], this population was defined by low birth weight (< 1500g), the incidence of BPD among such preterms being 140 cases per 1000.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Occurrence, predictive factors and associated morbidity of broncho-pulmonary dysplasia in a preterm birth cohort

Hakulinen¹,

Heinonen²,

Jokela³

et al. 1988

Jpme

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Occurrence, predictive factors and associated morbidity of broncho-pulmonary dysplasia in a preterm birth cohort

Hakulinen¹,

Heinonen²,

Jokela³

et al. 1988

Jpme

View full text Add to dashboard Cite

“…At this age, infants with BPD have been shown to have a mean height and weight less than two standard deviations below that of term newborns. 23,24 The degree of growth delay in infants with BPD is directly related to the severity and duration of the disease. 24 The cause of growth failure in such infants remains unclear.…”

Section: Characteristics Of Infants With Bpd M Akram Khan Et Almentioning

confidence: 99%

“…23,24 The degree of growth delay in infants with BPD is directly related to the severity and duration of the disease. 24 The cause of growth failure in such infants remains unclear. Most studies have evaluated infants after BPD has been well established.…”

Section: Characteristics Of Infants With Bpd M Akram Khan Et Almentioning

confidence: 99%

Site-specific characteristics of infants developing bronchopulmonary dysplasia

et al. 2006

View full text Add to dashboard Cite

Hypothesis: Site-specific variables that contribute to the pathogenesis of bronchopulmonary dysplasia (BPD) can be identified.Objectives: To evaluate the demographic, nutrition and growth characteristics of infants at risk for developing BPD at two neonatal intensive care units (NICUs: sites A and O).Study Design: Records of 306 infants of <30 weeks gestational age (GA) who survived to at least 36 weeks postmenstrual age were retrospectively reviewed. Data were obtained for maternal and neonatal demographics, weights, total fluids, calories, carbohydrate, protein and fat intake at birth, 7, 14, 21 and 28 days of life.Results: BPD rates were not different at the two sites. No statistical differences were noted in the incidence of maternal chorioamnionitis, pregnancy-induced hypertension or use of antenatal steroids among infants who developed BPD (n ¼ 169) and those who did not (n ¼ 137). White race, birth weight, respiratory distress syndrome requiring surfactant, sepsis and patent ductus arteriosus were significantly associated (all Pp0.03) with BPD. After controlling for significant confounding variables, infants who developed BPD had significantly (P<0.001) less weight gain, received less calories and fat in the first postnatal month. In the 26 to 28 weeks GA group, the odds of getting BPD were 5.4 (95%CI: 1.4 to 21.3) times greater for site A than site O (P ¼ 0.017).Conclusion: Our analysis suggests that while some decrease in BPD can be achieved by focusing on ventilation/oxygen use, this approach is unlikely to impact on the youngest infants.

show abstract

“…При этом частота формирования БЛД обратно про-порциональна гестационному возрасту, а также массе тела [1,10]. Проблема здоровья детей первых лет жизни с БЛД -это пре-жде всего высокий риск развития тяжёлых обострений заболевания на фоне респира-торных вирусных инфекций [2].…”

Section: казанский медицинский журнал 2015 г том 96 №4unclassified

Effect of monoclonal antibodies to respiratory syncytial virus in preterm children with bronchopulmonary dysplasia according to follow-up

et al. 2015

View full text Add to dashboard Cite

Aim. To assess the effect and safety of palivizumab to prevent the bronchopulmonary dysplasia complications in preterm children according to follow-up. Methods. The study included 48 very preterm infants (birth weight ranged from 732-1640 g) with bronchopulmonary dysplasia, who were divided into two groups. The main group included children who received passive immunization by palivizumab (31 children), the comparison group included un-immunized children (17 patients). The diagnosis of bronchopulmonary dysplasia in children at 28 days of postnatal life has been set according to clinical and radiological data. After being discharged from the department of pathology of newborn, children were followed-up for 12 months in the center of preterm children follow-up. Average age of patients with bronchopulmonary dysplasia was 4.2±1.3 months at passive immunization initiation. The drug was administered by intramuscular injection at a dose of 15 mg/kg once monthly. Results. Lower respiratory tract infections were observed in 6 (19.3%) patients from the first group, including 4 cases of obstructive bronchitis and 2 cases of pneumonia. These patients received incomplete course of immunization. In children who did not receive specific prophylaxis, respiratory infections were registered in 7 (41.2%) patients, with 2 cases accompanied by severe respiratory failure requiring mechanical ventilation. No adverse effects were identified while palivizumab treatment. Conclusion. Palivizumab is currently the only effective drug to prevent the severe respiratory syncytial virus infection; good safety of the drug makes it possible to reconsider the contraindication of its use in high-risk children with severe bronchopulmonary dysplasia.

show abstract

Growth and development of very low birthweight infants recovering from bronchopulmonary dysplasia.

Cited by 101 publications

References 11 publications

Occurrence, predictive factors and associated morbidity of broncho-pulmonary dysplasia in a preterm birth cohort

Occurrence, predictive factors and associated morbidity of broncho-pulmonary dysplasia in a preterm birth cohort

Site-specific characteristics of infants developing bronchopulmonary dysplasia

Effect of monoclonal antibodies to respiratory syncytial virus in preterm children with bronchopulmonary dysplasia according to follow-up

Contact Info

Product

Resources

About